The company reported Tuesday it brought in $1.7 million in its third quarter of 2024, up from $700,000 in the third quarter of 2023. It also reported a $27.4 million net loss, 24 cents per diluted share, in its third quarter this year, compared with $22 million in the third quarter of 2023.
“In general, things are going extremely well,” McClain said.
Absci hopes to use its AI platform to speed up the drug discovery process.
“We’re seeing results that we wouldn’t have seen with […]
Vancouver-based Absci marks major milestone in partnership with AstraZeneca on artificial …
NewsChest Technology site
